Cell-specific protein expression in Alzheimer's disease prefrontal cortex
Data files
Jul 15, 2025 version files 40.84 KB
-
Initial_Dataset_Protein.xlsx
37.23 KB
-
README.md
3.61 KB
Abstract
Analyzing the proteomes of different brain cell types is fundamental for understanding the pathophysiology of Alzheimer's disease (AD). However, spatial analysis of these diverse and limited cell populations poses significant challenges. The GeoMx Digital Spatial Profiler (DSP) platform analyzed protein levels in the prefrontal cortex of AD and non-AD brains. The platform interrogated 76 proteins and used immunofluorescence to distinguish between three cell types. Neprilysin, which promotes Aβ degradation, was significantly higher in AD neurons and microglia. LAMP2A level was higher in neurons of individuals with AD compared to a control group. Additionally, markers of neuroinflammation, such as CD11c, CD11b, and CD163, were also elevated in AD neurons. Our findings indicate that the DSP platform effectively facilitates cell-specific snapshots of the AD brain proteome.
Dataset DOI:
https://doi.org/10.5061/dryad.w6m905r12
GENERAL INFORMATION
1. Study Objective:
This dataset supports a spatial proteomics study investigating cell-specific alterations in protein expression within the prefrontal cortex (Brodmann area 8/9) in Alzheimer’s disease (AD). The analysis aims to characterize how protein signatures differ between AD and control samples at the cellular level, focusing on neurons, astrocytes, and microglia.
2.Authors Information:
- Principal Investigator Contact Information
Name: Mohammad Haeri, MD PhD
Institution: University Of Kansas Medical Center
Email: mhaeri@kumc.edu
-
First Author Contact Information
Name: Maryam Gholampour, PharmD Institution: University Of Kansas Medical Center Email: mgholampour@kumc.edu
3. Data Collection Dates: 2022-2023
4. Geographic Location:
Postmortem human brain tissue obtained from the University of Kansas Alzheimer’s Disease Research Center (KU ADRC) Neuropathology Core.
5. Funding Information:
National Institutes of Health Grant Number: P30 AG072973
SHARING / ACCESS INFORMATION
1. License:
CC0 1.0 Universal (CC0 1.0) Public Domain Dedication
2. Associated Publications:
Gholampour M, Basu MK, Swerdlow RH, Zhuo X, Haeri M. Cell-specific protein expression in Alzheimer’s disease prefrontal cortex. Alzheimer’s Dement. 2025; 21:e70339. https://doi.org/10.1002/alz.70339
3. Public Repository Hosting the Data:
Dryad Digital Repository
DATA & FILE OVERVIEW
File: Initial_Dataset_Protein.xlsx
Description:
This Excel file contains raw and processed protein expression data derived from the GeoMx Digital Spatial Profiler (NanoString Technologies) platform. Data represent spatially resolved proteomic profiles from formalin-fixed paraffin-embedded (FFPE) sections of human prefrontal cortex.
Total Number of Variables: 77 (including sample IDs and 76 protein measurements)
Number of Samples/ROIs: 8
Experimental Groups:
- Control samples: R001, R002, R003, R004
-
AD samples: R005, R006, R007, R008
EXPERIMENTAL DESIGN & METHODS
Tissue Source and Region:
Prefrontal cortex (Brodmann area 8/9) FFPE tissue from 4 AD patients and 4 age-matched non-demented controls.Spatial Proteomics Technique:
GeoMx Digital Spatial Profiler was used to analyze spatially defined 660 × 785 µm regions of interest (ROIs). ROIs were selected based on immunofluorescent staining with cell-type-specific markers:- Neurons: NeuN
- Microglia: Iba-1
- Astrocytes: GFAP
- Nuclear staining: SYTO 83
Protein Detection Method:
A panel of 76 oligonucleotide-tagged antibodies was used. After ROI definition and UV-mediated tag release, oligo barcodes were hybridized and quantified using the NanoString nCounter system.Data Processing:
- Protein counts were normalized using ERCC spike-in controls.
- Signal was adjusted using signal-to-noise ratios to correct for background.
- Data were log2-transformed for downstream analyses.
Human subjects data
The Kansas University Medical Center Human Subjects Committee (KUMC HSC) issued approval for all involvement of human subjects, and all participants provided informed consent prior to enrollment. This investigation was conducted in accordance with the Code of Ethics set forth by the World Medical Association (the Declaration of Helsinki).